Lisata Therapeutics Inc (LSTA)

[lunatick]

Event October STEM CELL MEETING ON THE MESA
October 7-9, 2015

http://stemcellmeetingonthemesa.com/scientific-symposium/poster-session/

"2015 POSTER ABSTRACTS
Every year, the Stem Cell Meeting on the Mesa invites the submission of abstracts that report new research developments in the areas of stem cell biology, stem cell medicine, regenerative medicine or ethical and regulatory issues. Please see the abstracts below which will be on display at the 2015 Scientific Symposium!

16. Functional Properties of Patient-derived Melanoma Cancer Stem Cells Utilized as Treatment for Metastatic Melanoma in a Phase III Clinical Trial

Presented by: Hans Keirstead, Caladrius Biosciences
Authors: Nistor, Gabriel; Poole, Aleksandra; Keirstead, Hans, Caladrius Biosciences, Inc.

Abstract:
Caladrius Biosciences is developing an innovative approach to cancer treatment that targets the cells responsible for tumor growth and metastasis, known as cancer stem cells (CSC) or tumor-initiating cells (TIC). The therapy uses purified autologous CSCs, derived from a patient’s own tumor and grown as a tumor cell line, as the antigen source of tumor-associated antigens to induce or enhance an anti-tumoral immune response. Using the immune system to target CSCs may provide a complementary or adjunctive therapy that could result in better long-term control, and possibly even a cure, of certain cancers. This approach has shown consistent and compelling results in sequential open-label and randomized phase 2 trials for advanced stage melanoma, and is now being tested in a phase 3 trial called the Intus Study. In order to demonstrate the tumor-initiating properties of purified patient-derived CSCs, we injected subcutaneously three different patient-established cell lines, at two different concentrations, in the flank of NOD/SCID mice. After 60 days, 80% of injected mice developed tumors that were phenotypically consistent with the markers of human melanoma cells. In order to determine whether isolated CSC populations contained antigenic cancer-related mutations, exomic sequencing was performed on tumor cell lines from 5 distinct melanoma tumors using Illumina’s sequencing technology. Sequencing results, combined with epigenetic data, indicated the presence of cancer and metastasis-related driver mutations with highly antigenic properties. Identification of these mutated antigens allows us to further study specific T-cell activation using mixed lymphocyte reaction assays. Concurrently, we analyzed patient serum samples before and 4 weeks after the first dose administration, using comprehensive high-throughput screening for proteins responsible for immune response, inflammation and angiogenesis. These analyses reveal a combination of humoral and cell immune responses, cytokine networks and serum tumor markers that are distinct in responsive versus non-responsive patients. Conclusion: Tumorigenicity and exomic analyses of patient-derived tumor cell lines isolated using our manufacturing procedure confirmed the tumor-initiating, highly antigenic nature of these cells, while the serum analyses demonstrated a distinct immune response upon administration of immunotherapy."

And PCT is named as a sponsor
http://stemcellmeetingonthemesa.com/sponsors/

2015 Company Presenters (Caladrius Biosiences)
http://stemcellmeetingonthemesa.com/partnering-forum/company-presentations/